Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 111-120 of 411 for multiple

Edit search filters
  1. A Study Comparing CAR-T Therapy Versus Pomalidomide, Bortezomib And Dexamethasone (PVd) Or Daratumumab, Pomalidomide And Dexamethasone (DPd) In Participants With Relapsed And Lenalidomide-Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ, Rochester, MN

  2. Lenalidomide And Low-Dose Dexamethasone In Patients With Previously Treated Multiple Myeloma And Kidney Dysfunction

    Scottsdale/Phoenix, AZ, Rochester, MN

  3. A Study Designed To Evaluate The Safety And Efficacy Of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) In Participants With T(11;14)-Positive Relapsed Or Refractory Multiple Myeloma

    Jacksonville, FL, Rochester, MN

  4. CC-220-MM-001: A Phase 1b/2a Multicenter, Open-Label, Dose-Escalation Study To Determine The Maximum Tolerated Dose, Assess The Safety, Tolerability, Pharmacokinetics And Efficacy Of CC-220 As Monotherapy And In Combination With Other Treatments In Subjects With Multiple Myeloma

    Scottsdale/Phoenix, AZ

  5. Daratumumab Retreatment In Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab Intravenous (Dara-IV)

    Rochester, MN

  6. A Phase III, Safety, Tolerability And Efficacy Of Combination Treatment Of BL-8040 And G-GSF As Compared To Placebo And G-CSF For ThE MobilizatioN Of HematopoiEtic Stem Cells For Autologous TransplantatIon In SubjectS With MM

    Rochester, MN

  7. A Study To Assess The Adverse Events And Change In Disease Activity In Adult Participants With Relapsed Or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets

    Rochester, MN

  8. Safety And Efficacy Of ALLO-605 An Anti-BCMA Allogeneic CAR T Cell Therapy In Patients With Relapsed/Refractory Multiple Myeloma

    Jacksonville, FL, Rochester, MN

  9. A Study Of Daratumumab, Bortezomib, Lenalidomide And Dexamethasone (DVRd) Followed By Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide And Dexamethasone (DVRd) Followed By Autologous Stem Cell Transplant (ASCT) In Participants With Newly Diagnosed Multiple Myeloma

    Rochester, MN

  10. A Study To Evaluate VSV-hIFNbeta-NIS To Treat Patients With Relapsed/Refractory Multiple Myleoma, Acute Myeloid Leukemia, Or T-cell Lymphoma

    Scottsdale/Phoenix, AZ, Rochester, MN

.

Mayo Clinic Footer